4.7 Article

Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 5, Pages 2376-2379

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02354-12

Keywords

-

Funding

  1. Astellas
  2. Cubist
  3. Forest
  4. Pfizer
  5. Novartis
  6. Rib-X
  7. NIH [R21A1092055-01, GM073898]
  8. Ortho-McNeil Pharmaceuticals
  9. Cubist Pharmaceuticals

Ask authors/readers for more resources

We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively. Beta-lactam exposure reduced overall vancomycin-Bodipy (dipyrromethene boron difluoride [4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene] fluorescent dye) binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available